Healthcare Services

An Important Factor Driving the Acute Respiratory Distress Syndrome (ARDS) Market Global Report 2026 Market Is the Increasing Number Of Respiratory Illness Are Anticipated To Positively Impact The Acute Respiratory Distress Syndrome (ARDS) Market

March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Acute Respiratory Distress Syndrome (ARDS) Market Expected To Change Between 2026 And 2030?

The market for acute respiratory distress syndrome (ards) has experienced swift expansion over recent years. Its valuation is set to increase from $1.41 billion in 2025 to $1.56 billion in 2026, with a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to several factors, including the rising incidence of respiratory infections, a growing hospital icu infrastructure, increasing awareness of ards management protocols, the limited availability of advanced ventilation devices, and the adoption of supportive care practices.

The market for acute respiratory distress syndrome (ARDS) is projected to experience substantial expansion over the coming years, reaching $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.7%. This anticipated growth is primarily due to technological innovations in mechanical ventilation and ECMO systems, heightened research and development efforts in ARDS therapeutics, the global expansion of critical care units, increased investment in customized patient management solutions, and the rising incidence of severe pneumonia and sepsis. Key trends anticipated during this period encompass the increased uptake of mechanical ventilation and ECMO devices, a higher prevalence of ARDS resulting from COVID-19 and other respiratory illnesses, the expanding application of sophisticated diagnostic tests for early identification, the growth of critical care and ICU infrastructure, and an emphasis on personalized and supportive patient care strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What Drivers Are Expected To Influence The Acute Respiratory Distress Syndrome (ARDS) Market During The Forecast Period?

The rising prevalence of respiratory illnesses is projected to fuel the growth of the acute respiratory distress syndrome (ARDS) market moving forward. Respiratory illness refers to a collection of medical conditions that impact the respiratory system, including the airways and lungs, often causing breathing difficulties. The increasing number of respiratory illnesses, such as COVID-19, stands as a major factor propelling the expansion of the acute respiratory distress syndrome (ARDS) market. As more individuals contract respiratory illnesses, the need for ARDS treatments and therapies is expected to rise, thereby stimulating market growth. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, Australia recorded a total of 474 asthma-related deaths in 2023, consisting of 325 females and 149 males. This statistic is nearly identical to the 473 asthma-related deaths reported in 2022, highlighting a stable trend in asthma mortality over these two years. Consequently, the escalating number of respiratory illnesses is driving the growth of the acute respiratory distress syndrome (ARDS) market.

How Is The Acute Respiratory Distress Syndrome (ARDS) Market Structured Across Different Segments?

The acute respiratory distress syndrome (ards) market covered in this report is segmented –

1) By Type: Diagnosis, Treatment

2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

3) By Severity: Mild, Moderate, Severe

4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

Subsegments:

1) By Diagnosis: Imaging Tests, Blood Tests

2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

Which Trends Are Shaping The Future Of The Acute Respiratory Distress Syndrome (ARDS) Market?

Within the acute respiratory distress syndrome market, key companies are concentrating on creating sophisticated immune modulators with the goal of improving patient survival rates and diminishing inflammation. These immune modulators are therapeutic approaches designed to restore the immune system’s balance by addressing problematic inflammatory pathways, all without broadly suppressing immune function. An example of this is BioAegis Therapeutics, a clinical-stage company based in the US, which in June 2025, obtained FDA Fast Track designation for its primary candidate, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This particular therapy functions by replenishing gelsolin, an essential protein for immune regulation, thereby regulating NLRP3 inflammasome activation, boosting microbial clearance, eliminating harmful actin and inflammatory agents, and controlling macrophage activity. The rhu-pGSN product is currently undergoing evaluation in a global Phase 2b trial involving 600 patients with moderate to severe ARDS, and it might also become accessible via the FDA Expanded Access or Compassionate Use program. The Fast Track designation provides several benefits, including streamlined regulatory interactions, a rolling review process for marketing applications, and qualification for priority review. These advantages could hasten its market entry and provide a new treatment choice for patients who have few other options.

Which Major Players Dominate The Acute Respiratory Distress Syndrome (ARDS) Market?

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

Read the full acute respiratory distress syndrome (ards) market report here:

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Which Region Is Forecast To Lead The Acute Respiratory Distress Syndrome (ARDS) Market In Terms Of Market Size?

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acute Respiratory Distress Syndrome (ARDS) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

severe acute respiratory syndrome treatment global market report

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

respiratory disease testing global market report

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

acute coronary syndrome global market report

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795